Globe Life Inc. · GL · FY2025 Q3 · Calendar Q4 2025

Globe Life: Strong Q3, Higher Earnings Outlook, Execution Risks Remain

The quarter supports a constructive but conditional view of Globe Life: underwriting performance and favorable mortality supported earnings growth, while modest premium growth and dependence on future reinsurance and assumption outcomes temper the outlook.

Reported After market closeNYSEFinancial Services $12.86B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $4.81 Consensus $4.60
EPS surprise +4.6% Reported versus consensus
Reported revenue $1.51B Consensus $1.52B
Revenue surprise -0.4% Reported versus consensus

Market reaction

event-close to next-session close
Stock move +0.1% Event window
SPY move +0.6% Same window
Abnormal move -0.5% Stock minus SPY
Volume 1.5× Versus trailing sessions
Subsequent drift -3.9% Up to 20 sessions
GLSPY benchmark

Ask FN2 about GL FY2025 Q3

Transcript, numbers and history already loaded

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior-quarter analysis, Globe Life reported a stronger Q3, raised full-year earnings guidance, added detail on worksite and recruiting technology, and continued progress on the Bermuda reinsurance affiliate.

Guidance delta

Management raised 2025 net operating earnings guidance while reaffirming 2025 premium growth guidance of 6%-7%.

Key takeaways

  • Q3 net income was $388 million, with improved underwriting margins and a 38% increase in net operating income.
  • Premium growth remained modest at 5% in life and 9% in health, while full-year earnings guidance increased.
  • Management emphasized agency expansion, worksite enrollment, recruiting technology, and progress toward Bermuda reinsurance.

Management priorities

  • Expand the exclusive agency force and improve recruiting visibility through the enterprise recruiting CRM.
  • Complete the worksite enrollment platform rollout and continue technology and sales investments.
  • Advance the Bermuda reinsurance affiliate through regulatory approvals and execute the planned transaction.

Follow GL with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
GL EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q1 '24 estimate $2.79 Q1 '24 actual $2.78, match Q2 '24 estimate $2.91 Q2 '24 actual $2.97, beat Q3 '24 estimate $3.06 Q3 '24 actual $3.49, beat Q2 '25 estimate $3.25 Q2 '25 actual $3.27, beat Q3 '25 estimate $4.60 Q3 '25 actual $4.81, beat Q4 '25 estimate $3.44 Q4 '25 actual $3.39, miss Q1 '26 estimate $3.47 Q1 '26 actual $3.43, miss Q2 '26 estimate $3.67 Q2 '26 actual $3.61, miss Q3 '26 estimate $4.92 Q4 '26 estimate $3.78 Q1 '27 estimate $3.88 Q2 '27 estimate $4.03
Show 1 more >

Analyst Consensus ?

ConsensusHold28 ratings
Bullish1035.7%
Neutral1139.3%
Bearish725.0%

Analyst 52W Price Targets

$165.68Current
$90Low
$154.77Average
$200High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 4, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Keefe, Bruyette & Woods Outperform OutperformMaintainJul 24, 2026
TD Cowen Buy BuyMaintainJul 22, 2026
JP Morgan Overweight OverweightMaintainJul 21, 2026
Piper Sandler Overweight OverweightMaintainJul 15, 2026
Evercore ISI Group In Line In LineMaintainJul 13, 2026
Show 23 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $165.68. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Piper SandlerPaul Newsome$200$178.99 +20.7%Jul 15, 2026
JefferiesAnalyst unavailable$166$178.86 +0.2%Jul 10, 2026
Piper SandlerAnalyst unavailable$175$156.28 +5.6%May 26, 2026
Morgan StanleyAnalyst unavailable$181$155.3 +9.2%May 21, 2026
Truist FinancialMark Hughes$185$153.55 +11.7%Apr 24, 2026
See 26 more

Track every rating change on GL the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Globe Life Inc. delivers diverse life insurance and supplementary health coverage, alongside annuity products, targeting households in the lower-middle to middle-income brackets throughout the United States. The company's operations are structured into four key segments: Life Insurance, Supplemental Health Insurance, Annuities, and Investments. Its offerings encompass whole life, term life, and other life protection plans; supplemental health benefits like Medicare supplements, critical illness, and accident policies; and both single-premium and flexible-premium deferred annuities. Founded in 1979 and headquartered in McKinney, Texas, the enterprise rebranded from Torchmark Corporation to Globe Life Inc. in August 2019.

Historical context

All GL earnings

Financial Services peers this season

Latest reports in the same sector

Latest beats and misses

Who reports next

Get the GL recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-10-04T08:10:42.068708+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-04T08:10:42.065065+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-04. For educational purposes only; not investment advice.